Literature DB >> 10652485

Schistosomiasis vaccines: a devils' advocate view.

B Gryseels1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10652485     DOI： 10.1016/s0169-4758(99)01597-5

Source DB:  PubMed          Journal:  Parasitol Today        ISSN： 0169-4758


× No keyword cloud information.
  7 in total

1.  Molecular evidence supports an african affinity of the neotropical freshwater gastropod, Biomphalaria glabrata, say 1818, an intermediate host for Schistosoma mansoni.

Authors:  G Campbell; C S Jones; A E Lockyer; S Hughes; D Brown; L R Noble; D Rollinson
Journal:  Proc Biol Sci       Date:  2000-12-07       Impact factor: 5.349

2.  Cellular and humoral immune responses and protection against schistosomes induced by a radiation-attenuated vaccine in chimpanzees.

Authors:  M Eberl; J A Langermans; P A Frost; R A Vervenne; G J van Dam; A M Deelder; A W Thomas; P S Coulson; R A Wilson
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 3.  Human hookworm infection in the 21st century.

Authors:  Simon Brooker; Jeffrey Bethony; Peter J Hotez
Journal:  Adv Parasitol       Date:  2004       Impact factor: 3.870

Review 4.  Global change and human vulnerability to vector-borne diseases.

Authors:  Robert W Sutherst
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

Review 5.  Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges.

Authors:  Rashad Abdul-Ghani; Naguiba Loutfy; Amel el-Sahn; Azza Hassan
Journal:  Parasitol Res       Date:  2009-03-03       Impact factor: 2.289

6.  The schistosomiasis research agenda--what now?

Authors:  Jeffrey M Bethony; Alex Loukas
Journal:  PLoS Negl Trop Dis       Date:  2008-02-27

7.  Trick or treat: the role of vaccines in integrated schistosomiasis control.

Authors:  Robert Bergquist; Jürg Utzinger; Donald P McManus
Journal:  PLoS Negl Trop Dis       Date:  2008-06-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.